Mubadala Investment Co PJSC
Known title: 10% OwnerCIK: 0001704268
Mubadala Investment Co PJSC's purchase track record
How the stock did after each of Mubadala Investment Co PJSC's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
6
of 6 since December 23, 2022
Stock higher 6 months later
67%
3 months: 33%
Median 6-month return
+13.8%
3 months: -11.9%
Beat the S&P 500
50%
median +2.1% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 3/1/2023 | RXRX | $910K | +10.3% | +10.7% | +14.3% |
| 2/21/2023 | RXRX | $2.78M | +20.0% | +17.8% | +9.8% |
| 2/10/2023 | RXRX | $1.22M | -35.4% | +16.9% | +9.1% |
| 1/25/2023 | RXRX | $261K | -39.5% | +65.8% | +13.7% |
| 1/3/2023 | RXRX | $4.00M | -13.0% | -3.4% | +16.3% |
| 12/23/2022 | RXRX | $3.73M | -10.9% | -2.0% | +13.1% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| RXRX | ▲ Buy | Open Market | 66,822 | $522K | 3/2/2023 | View on chart |
| RXRX | ▲ Buy | Open Market | 48,867 | $388K | 3/1/2023 | View on chart |
| RXRX | ▲ Buy | Open Market | 815 | $6K | 2/28/2023 | View on chart |
| RXRX | ▲ Buy | Open Market | 52,500 | $404K | 2/27/2023 | View on chart |
| RXRX | ▲ Buy | Open Market | 109,118 | $834K | 2/24/2023 | View on chart |
| RXRX | ▲ Buy | Open Market | 51,864 | $404K | 2/23/2023 | View on chart |
| RXRX | ▲ Buy | Open Market | 50,941 | $399K | 2/22/2023 | View on chart |
| RXRX | ▲ Buy | Open Market | 94,418 | $731K | 2/21/2023 | View on chart |
| RXRX | ▲ Buy | Open Market | 63,382 | $489K | 2/17/2023 | View on chart |
| RXRX | ▲ Buy | Open Market | 42,682 | $337K | 2/16/2023 | View on chart |
| RXRX | ▲ Buy | Open Market | 6,300 | $50K | 2/14/2023 | View on chart |
| RXRX | ▲ Buy | Open Market | 32,474 | $259K | 2/13/2023 | View on chart |
| RXRX | ▲ Buy | Open Market | 11,000 | $88K | 2/10/2023 | View on chart |
| RXRX | ▲ Buy | Open Market | 600 | $5K | 2/1/2023 | View on chart |
| RXRX | ▲ Buy | Open Market | 7,886 | $63K | 1/26/2023 | View on chart |
| RXRX | ▲ Buy | Open Market | 24,526 | $193K | 1/25/2023 | View on chart |
| RXRX | ▲ Buy | Open Market | 69,518 | $537K | 1/10/2023 | View on chart |
| RXRX | ▲ Buy | Open Market | 76,046 | $581K | 1/9/2023 | View on chart |
| RXRX | ▲ Buy | Open Market | 68,953 | $511K | 1/6/2023 | View on chart |
| RXRX | ▲ Buy | Open Market | 80,035 | $591K | 1/5/2023 | View on chart |
| RXRX | ▲ Buy | Open Market | 91,892 | $717K | 1/4/2023 | View on chart |
| RXRX | ▲ Buy | Open Market | 141,646 | $1.1M | 1/3/2023 | View on chart |
| RXRX | ▲ Buy | Open Market | 99,754 | $754K | 12/30/2022 | View on chart |
| RXRX | ▲ Buy | Open Market | 84,622 | $653K | 12/29/2022 | View on chart |
| RXRX | ▲ Buy | Open Market | 71,299 | $512K | 12/28/2022 | View on chart |
| RXRX | ▲ Buy | Open Market | 145,652 | $1.1M | 12/27/2022 | View on chart |
| RXRX | ▲ Buy | Open Market | 100,378 | $754K | 12/23/2022 | View on chart |
| RXRX | ▲ Buy | Grant | 2,551,020 | $25.0M | 10/27/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
Recursion Pharmaceuticals Stock Falls as Cathie Wood Adjusts Biotech Holdings
Recursion Pharmaceuticals shares have declined recently while the broader market improved. This movement coincides with Cathie Wood's recent portfolio adjustments, where she increased positions in several biotech stocks while reducing others. The stock is currently trading near the middle of its 52-week range, with analysts maintaining an average target price of $7.22.
Recursion Pharmaceuticals Stock Falls as Cathie Wood Adjusts Biotech Holdings. Recursion Pharmaceuticals shares have declined recently while the broader market improved. This movement coincides with Cathie Wood's recent portfolio adjustments, where she increased positions in several biotech stocks while reducing others. The stock is currently trading near the middle of its 52-week range, with analysts maintaining an average target price of $7.22.